Tirzepatide (development code LY3298176) is a synthetic peptide from Eli Lilly that activates two gut-hormone receptors at once: GIP and GLP-1. It was the first “dual agonist” of its kind to be approved, and it is sold as Mounjaro (type 2 diabetes) and Zepbound (chronic weight management and obstructive sleep apnea).
This guide explains what tirzepatide is, why it counts as a peptide, how it works at each receptor, what its structure and half-life look like, and how it compares with semaglutide.
Tirzepatide at a glance
| Developer | Eli Lilly and Company |
|---|---|
| Code name | LY3298176 |
| Brand names | Mounjaro, Zepbound |
| Type | Synthetic peptide (39 amino acids) with a fatty-acid side chain |
| Receptors activated | GIP and GLP-1 (a “dual agonist”) |
| Molecular weight | About 4,813 g/mol |
| Molecular formula | C225H348N48O68 |
| CAS number | 2023788-19-2 |
| Half-life | About 5 days (once-weekly) |
| FDA approvals | Type 2 diabetes (2022), chronic weight management (2023), obstructive sleep apnea with obesity (2024) |
Is tirzepatide a peptide?
Yes. Tirzepatide is a peptide: a chain of 39 amino acids. Its sequence is based on GIP, the body’s own “glucose-dependent insulinotropic polypeptide,” modified so it also switches on the GLP-1 receptor. Two of its building blocks are a non-natural amino acid called aminoisobutyric acid (Aib), which protects it from the enzyme DPP-4 that breaks down natural GIP and GLP-1 in minutes.
That peptide structure is also why tirzepatide is injected. Taken by mouth, a peptide this size is broken down by stomach acid and digestive enzymes before it can be absorbed.
How does tirzepatide work?
Tirzepatide’s mechanism of action comes from its two receptors. Both belong to the incretin system, the hormones the gut releases after a meal to help the body handle incoming food.
The GLP-1 receptor
GLP-1 receptor activation increases insulin release when blood sugar is high, lowers glucagon after meals, slows stomach emptying, and acts on appetite centers in the brain to increase fullness and reduce food intake.
The GIP receptor
GIP also increases glucose-dependent insulin release. It acts on fat tissue, where it is involved in how fat is stored and handled, and on the brain. Pairing GIP with GLP-1 was long debated, because GIP alone has little effect in type 2 diabetes. Tirzepatide’s trial results showed the combination could outperform GLP-1 activity alone, which revived interest in GIP as a target.
An “imbalanced” dual agonist
Tirzepatide does not hit both receptors equally. In lab studies it bound the GIP receptor about as strongly as native GIP, but bound the GLP-1 receptor roughly five times more weakly than native GLP-1. At the GLP-1 receptor it also shows biased signaling: it favors the cAMP pathway over beta-arrestin recruitment, which leads to less receptor internalization. Researchers think this tuning is part of why it works as well as it does.
Is tirzepatide a GLP-1?
It is often called a GLP-1 drug because it activates the GLP-1 receptor, but it is more accurately a dual GIP/GLP-1 receptor agonist. In fact, it favors GIP.
Tirzepatide’s structure
- A GIP-based backbone of 39 amino acids, ending in an amide group.
- Aib substitutions at positions 2 and 13 that block breakdown by DPP-4.
- A C20 fatty diacid side chain attached to the lysine at position 20 through a linker. This lets tirzepatide bind to albumin in the blood, which shields it from kidney clearance and stretches its action over days.
Tirzepatide half-life
Tirzepatide has a half-life of about 5 days. Thanks to the albumin binding described above, that is long enough for a once-weekly schedule, compared with a few minutes for natural GIP and GLP-1.
Approvals and clinical trials
Tirzepatide was studied in two large Phase 3 programs:
- SURPASS (type 2 diabetes): tirzepatide lowered HbA1c (average blood sugar) and body weight more than the comparators it was tested against, including semaglutide 1 mg in SURPASS-2. This led to FDA approval as Mounjaro in May 2022.
- SURMOUNT (obesity): in SURMOUNT-1 (New England Journal of Medicine, 2022), mean weight reduction at 72 weeks reached 20.9% in the highest-dose group versus 3.1% with placebo. This led to approval as Zepbound in November 2023, and Zepbound was approved for obstructive sleep apnea in adults with obesity in December 2024.
Tirzepatide vs semaglutide
Semaglutide (Ozempic, Wegovy) activates only the GLP-1 receptor; tirzepatide activates GIP and GLP-1. The two were compared directly in SURMOUNT-5 (New England Journal of Medicine, 2025), a head-to-head trial in adults with obesity: at 72 weeks, mean weight reduction was 20.2% with tirzepatide versus 13.7% with semaglutide.
| Semaglutide | Tirzepatide | |
|---|---|---|
| Receptors | GLP-1 | GIP + GLP-1 |
| Length | 31 amino acids | 39 amino acids |
| Half-life | About 7 days | About 5 days |
| Developer | Novo Nordisk | Eli Lilly |
| Brand names | Ozempic, Wegovy, Rybelsus (oral) | Mounjaro, Zepbound |
The next step in this line is retatrutide, which adds the glucagon receptor. See What Is Retatrutide? and Retatrutide vs Tirzepatide.
Side effects and warnings
From the approved prescribing information and the trials:
- The most common side effects are gastrointestinal: nausea, diarrhea, vomiting, constipation, indigestion and abdominal pain, most often during dose increases.
- The label carries a boxed warning about thyroid C-cell tumors, based on findings in rodents. It is not to be used by people with a personal or family history of medullary thyroid carcinoma or with MEN 2.
- Other warnings include pancreatitis, gallbladder problems, low blood sugar when combined with insulin or sulfonylureas, kidney problems from dehydration, and serious allergic reactions.
Frequently asked questions
Is tirzepatide a peptide?
Yes. It is a synthetic peptide of 39 amino acids with a fatty-acid side chain that lets it bind albumin and last for days.
How does tirzepatide work?
It activates the GIP and GLP-1 receptors. Together they increase glucose-dependent insulin release, reduce glucagon after meals, slow stomach emptying and act on appetite centers in the brain.
Is tirzepatide a GLP-1?
It activates the GLP-1 receptor, but it is a dual agonist: it also activates the GIP receptor, and it binds GIP more strongly.
What is the half-life of tirzepatide?
About 5 days, which is why it is given once a week.
Why is there no oral tirzepatide?
As a large peptide, it would be broken down by stomach acid and digestive enzymes and poorly absorbed, so it is given by injection.
Sources
- Coskun T, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus. Molecular Metabolism, 2018.
- Willard FS, et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight, 2020.
- Frias JP, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2). New England Journal of Medicine, 2021.
- Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine, 2022.
- Aronne LJ, et al. Tirzepatide as compared with semaglutide for the treatment of obesity (SURMOUNT-5). New England Journal of Medicine, 2025.
- Mounjaro and Zepbound U.S. prescribing information, Eli Lilly and Company.
This article is for educational purposes only and is not medical advice.